The study, published in European Urology, examined whether conventional findings in prostate tissue removed during surgery could predict the effectiveness of androgen-deprivation therapy when combined with postoperative radiotherapy. The investigators found that these features were strongly associated with a patient’s overall prognosis, but they did not identify a subgroup that gained a greater survival advantage from hormone therapy.

The distinction is clinically important. After prostatectomy, some men have detectable or rising prostate-specific antigen, or PSA, or pathological evidence suggesting that cancer could return. Radiation therapy may then be directed at the surgical bed and nearby tissues. Hormone therapy, also called androgen-deprivation therapy, suppresses testosterone and other androgen signals that can stimulate prostate cancer cells. Although the combination can improve outcomes in selected patients, hormone therapy may also cause hot flashes, fatigue, sexual dysfunction, loss of bone density, weight gain and metabolic changes.

To investigate whether pathology could guide that decision, the research team assembled individual patient data from five phase 3 randomized clinical trials. Together, the studies included 4,781 men who had undergone prostate cancer surgery and subsequently received radiation therapy, either alone or with hormone therapy. Pooling patient-level data allowed the researchers to examine treatment effects across clinically relevant subgroups rather than relying only on broad results from separate trials.

The investigators created an adverse feature count based on four pathological findings associated with aggressive disease. These included Grade Group 4 or 5 cancer, invasion of the seminal vesicles, extension of cancer beyond the prostate and positive surgical margins, in which malignant cells are found at the edge of the removed tissue. Each patient received a score from zero to four according to the number of features present.

The results confirmed that the score was prognostic. In other words, men with more adverse features generally faced a higher risk of cancer spreading, or metastasizing, and a higher risk of death. High-grade tumors reflect more abnormal cellular behavior, while extraprostatic extension and seminal vesicle invasion indicate that the tumor has penetrated beyond the prostate’s main boundaries. Positive margins suggest that microscopic disease may remain after surgery.

Yet the same score was not predictive of treatment benefit. Statistical analyses found no evidence that men with multiple adverse pathological features experienced a larger improvement in overall survival or metastasis-free survival when hormone therapy was added to radiation. Patients with fewer risk factors did not appear to be the only group benefiting, nor did those with the most aggressive pathological profiles show a clearly amplified response.

This finding illustrates a central concept in precision oncology. A prognostic biomarker estimates how a disease is likely to behave regardless of treatment, while a predictive biomarker indicates whether a particular therapy is more or less likely to work. The pathological features examined in this analysis functioned as prognostic markers, but they did not demonstrate the treatment-interaction effect required to guide hormone therapy decisions.

The pattern remained consistent among men whose PSA level was 0.5 nanograms per milliliter or less before radiation. Previous research has suggested that the overall advantage of adding hormone therapy may be limited in this setting, making the question of patient selection especially relevant. The new analysis indicates that traditional postoperative pathology does not solve that selection problem, even when several high-risk features are present.

“These findings highlight an important distinction between predicting risk and predicting treatment benefit,” said lead investigator Dr. Amar Kishan, professor and executive vice chair of radiation oncology at the David Geffen School of Medicine at UCLA. Kishan said the results point to the need for molecular biomarkers capable of revealing tumor biology and identifying which patients are genuinely sensitive to hormone suppression. Such tools could help clinicians intensify treatment for men likely to benefit while sparing others from avoidable toxicity.

The study’s senior author was Dr. Daniel Spratt of University Hospitals Seidman Cancer Center and Case Western Reserve University. The UCLA research team included Tahmineh Romero-Kalbasi, Dr. Michael Steinberg, Dr. Luca Valle, Dr. Kekoa Taparra, Dr. Matthew J. Farrell, Dr. Matthew Rettig, Dr. Adam Singer, Dr. Nikita Baclig, Dr. Robert Reiter, Dr. Scott Eggener, Dr. Wayne Brisbane and Dr. Nicholas Nickols. The investigators’ conclusion is not that pathology has lost its value, but that risk classification alone cannot determine treatment response. Future approaches may combine pathological assessment with genomic signatures, immune markers, imaging and other molecular measurements to make postoperative prostate cancer treatment more precise.

Subject of Research: Prostate cancer treatment response after surgery, with a focus on postoperative radiation therapy and hormone therapy.

News Publication Date: Not provided.

Web References: UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer ; Dr. Amar Kishan: https://www.uclahealth.org/providers/amar-kishan

References: European Urology, DOI: 10.1016/j.eururo.2026.07.013

Keywords: Prostate cancer, prostate tumors, radiation therapy, hormone therapy, androgen-deprivation therapy, prostatectomy, pathological risk factors, metastasis-free survival, overall survival, cancer biomarkers, precision oncology, clinical trials, UCLA Health

At the crux of this therapeutic intensification is the integration of androgen receptor pathway inhibitors (ARPIs), chemotherapeutic agents like docetaxel, and targeted radiotherapy. ARPIs such as enzalutamide, apalutamide, and darolutamide disrupt androgen signaling at various junctures, effectively incapacitating tumor growth pathways that remain active despite castration levels of testosterone. Meanwhile, docetaxel, a microtubule inhibitor, enhances cytotoxicity when paired with ADT. Radiotherapy directed at primary prostate tumors or metastatic sites adds a locoregional dimension to systemic treatment. This multifaceted approach harnesses biologic vulnerabilities and strategically attacks prostate cancer on multiple fronts, thereby improving progression-free and overall survival metrics, especially among select patient cohorts.

The classification of hormone-sensitive prostate cancer hinges fundamentally on the clinical history and disease burden at presentation. Patients fall into two principal categories: those with localized prostate cancer treated definitively before systemic features evolve, and those diagnosed de novo with metastatic disease. Further stratification relies on imaging assessments that delineate the extent and anatomical distribution of metastases. Conventional modalities like computed tomography (CT) and whole-body bone scintigraphy have been the mainstay. However, these methods possess inherent limitations, notably in resolution and sensitivity for microscopic or low-volume metastatic involvement. Consequently, clinical decision-making based solely on traditional imaging can underestimate disease extent, potentially leading to suboptimal treatment choices.

Enter prostate-specific membrane antigen (PSMA) positron emission tomography (PET), a transformative imaging technology that substantially redefines the detection landscape in prostate cancer. PSMA PET provides exquisite sensitivity and spatial resolution, enabling visualization of metastatic deposits that evade standard imaging detection thresholds. This leap in diagnostic capability allows for earlier identification of metastatic disease, uncovering previously unrecognized patient subsets with low-volume metastases or oligometastatic states. Such fine-grained biological and anatomical insight offers unprecedented opportunities to tailor systemic and local therapeutic strategies to the individual patient’s disease phenotype, fostering truly personalized treatment intensification.

Nonetheless, the clinical utility of incorporating PSMA PET into routine staging and treatment algorithms remains an active area of investigation and debate. On one hand, detecting micrometastatic spread can prompt incorporation of docetaxel into ADT plus ARPI regimens, conferring a survival advantage in certain groups. On the other, patients with minimal disease burden discerned only on PSMA PET may derive limited incremental benefit from adding chemotherapy, exposing them unnecessarily to toxicity. The challenge lies in calibrating treatment intensity commensurate to the biological aggressiveness and visibility of metastases on advanced imaging, ensuring that the added treatment burden is justified by clinical gains.

Personalized management of non-metastatic hormone-sensitive prostate cancer (nmHSPC) now incorporates novel strategies that balance aggressive therapy with quality of life considerations. Radiotherapy directed at the primary tumor in conjunction with systemic therapy has emerged as a critical intervention, especially in patients with high-risk localized disease. Recent evidence indicates that delivering definitive radiotherapy can improve metastasis-free survival and potentially overall survival. Additionally, ARPIs augment treatment efficacy in nmHSPC by suppressing androgen receptor signaling more robustly than ADT alone, delaying progression to metastatic castration-resistant prostate cancer.

In the metastatic hormone-sensitive prostate cancer (mHSPC) setting, risk and volume stratification profoundly influence treatment selection. High-volume metastatic disease, characterized by extensive visceral or bone involvement, benefits disproportionately from intensified regimens including docetaxel combined with ADT and an ARPI. Conversely, patients with low-volume disease may be spared the toxicities of chemotherapy without compromising outcomes, relying instead on combination ADT and ARPI approaches. This nuanced tailoring of therapy underscores the importance of accurate disease characterization via comprehensive imaging and clinical evaluation.

Recent therapeutic developments are expanding the armamentarium for mHSPC beyond established agents. AKT inhibitors, which target a critical node in the PI3K/AKT/mTOR pathway frequently dysregulated in prostate cancer, show promise in early-phase trials, particularly for tumors harboring pathway alterations. Parallelly, radioligand therapies employing novel isotopes conjugated to PSMA ligands allow targeted delivery of cytotoxic radiation directly to prostate cancer cells, potentially improving control with reduced systemic side effects. Poly ADP-ribose polymerase (PARP) inhibitors, initially developed for homologous recombination repair-deficient tumors, are being evaluated in mHSPC settings to exploit DNA repair vulnerabilities early in disease evolution.

As the therapeutic complexity escalates, mitigation of toxicity assumes critical importance in long-term management. Strategies to reduce adverse effects span from optimized dosing schedules, the judicious use of growth factor support with chemotherapy, to vigilant monitoring of cardiovascular, metabolic, and neurocognitive domains affected by prolonged androgen suppression. Emerging data underscore the necessity of multidisciplinary care teams, integrating oncology, urology, radiation therapy, and supportive care specialists to individualize treatment and preserve patient quality of life.

Moreover, the heterogeneity of prostate cancer biology embedded in genomic, transcriptomic, and microenvironmental factors calls for integration of molecular profiling into clinical algorithms. Attempts to incorporate biomarkers predictive of response to ARPIs, chemotherapy, and targeted agents are underway, aiming to refine patient selection further. Personalized medicine in HSPC thus rests on a triad of improved imaging diagnostics, comprehensive clinical and molecular risk stratification, and the availability of diverse therapeutic modalities.

This transformative approach reshapes not only treatment paradigms but also patient expectations and survivorship frameworks. Patients previously relegated to ADT monotherapy now anticipate more aggressive yet personalized regimens that offer hope for prolonged disease control. At the same time, balancing intensity with tolerability necessitates shared decision-making, with clinicians guiding patients through increasingly complex benefit-risk landscapes.

In conclusion, the management of hormone-sensitive prostate cancer is experiencing a renaissance driven by intensified treatment strategies grounded in profound biological insights and cutting-edge diagnostic tools. The deployment of androgen receptor pathway inhibitors, chemotherapy, and targeted radiotherapy, individually or in combination, marks a decisive departure from traditional monotherapy approaches. Novel agents targeting molecular pathways and employing innovative delivery mechanisms promise further improvements in outcomes. The advent of PSMA PET imaging illuminates metastatic spread with unprecedented precision, enabling more nuanced treatment selection. Together, these advancements empower clinicians to personalize and intensify therapy, aiming to optimize survival and maintain quality of life for patients navigating the evolving landscape of hormone-sensitive prostate cancer.

Subject of Research: Hormone-sensitive prostate cancer and personalized treatment intensification strategies

Article Title: Personalized intensification of treatment for hormone-sensitive prostate cancer

Article References:
Cilento, M.A., Butler, L.M., Emmett, L. et al. Personalized intensification of treatment for hormone-sensitive prostate cancer. Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01100-3

Image Credits: AI Generated